key: cord-0870171-nj7iji78
authors: Brouwer, Philip J.M.; Brinkkemper, Mitch; Maisonnasse, Pauline; Dereuddre-Bosquet, Nathalie; Grobben, Marloes; Claireaux, Mathieu; de Gast, Marlon; Marlin, Romain; Chesnais, Virginie; Diry, Ségolène; Allen, Joel D.; Watanabe, Yasunori; Giezen, Julia M.; Kerster, Gius; Turner, Hannah L.; van der Straten, Karlijn; van der Linden, Cynthia A.; Aldon, Yoann; Naninck, Thibaut; Bontjer, Ilja; Burger, Judith A.; Poniman, Meliawati; Mykytyn, Anna Z.; Okba, Nisreen M.A.; Schermer, Edith E.; van Breemen, Marielle J.; Ravichandran, Rashmi; Caniels, Tom G.; van Schooten, Jelle; Kahlaoui, Nidhal; Contreras, Vanessa; Lemaître, Julien; Chapon, Catherine; Tsong Fang, Raphaël Ho; Villaudy, Julien; Sliepen, Kwinten; van der Velden, Yme U.; Haagmans, Bart L.; de Bree, Godelieve J.; Ginoux, Eric; Ward, Andrew B.; Crispin, Max; King, Neil P.; van der Werf, Sylvie; van Gils, Marit J.; Le Grand, Roger; Sanders, Rogier W.
title: Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
date: 2021-01-26
journal: Cell
DOI: 10.1016/j.cell.2021.01.035
sha: 4fef52e40d350c12ccd7b9d9655bbb3d7b4d73ef
doc_id: 870171
cord_uid: nj7iji78

The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across 89 the globe and infected more than 46 million individuals since late 2019 90

(https://covid19.who.int/). SARS-CoV-2 causes coronavirus disease 2019 (COVID-19), 91

which manifests itself as a mild respiratory illness in most infected individuals, but can lead 92

to acute respiratory distress syndrome and death in a significant percentage of cases. As of protein nanoparticles significantly improved NAb titers, which supports pursuing this platform 142

for the generation of nanoparticle immunogens displaying prefusion SARS-CoV-2 S proteins.

Here, we describe the generation and characterization of two-component protein 145 nanoparticles displaying stabilized prefusion SARS-CoV-2 S proteins. Immunization studies 146 in mice, rabbits and macaques demonstrated that these nanoparticles induce robust humoral 147

responses. Vaccinated macaques challenged with a high dose of SARS-CoV-2 virus had 148

strongly reduced viral loads in both the upper and lower respiratory tracts, and developed 149 less lung lesions when compared to unvaccinated animals. 150 151

SARS-CoV-2 S proteins can be displayed on two component I53-50 nanoparticles 154 155

The computationally designed I53-50 nanoparticle (I53-50NP) constitutes twenty trimeric 156 (I53-50A or variants thereof) and twelve pentameric (I53-50B.4PT1) subunits which self-157 assemble to form monodisperse icosahedral particles with a diameter of approximately 30 158

nm (Bale et al., 2016) . To generate I53-50NPs presenting SARS-CoV-2 S proteins, we 159

genetically fused the C-terminus of the previously described stabilized prefusion S protein to 160 the N-terminus of the I53-50A variant, I53-50A.1NT1, using a glycine-serine linker ( Figure  161 1A) (Brouwer et al., 2020) . The fusion protein was purified from transfected human 162 embryonic kidney (HEK) 293F cell supernatant using Ni-NTA purification followed by size-163 exclusion chromatography (SEC). Collection of the appropriate SEC fractions yielded ~2 164 mg/L of trimeric SARS-CoV-2 S-I53-50A.1NT1 fusion protein ( Figure 1B ). To initiate 165

assembly of nanoparticles presenting SARS-CoV-2 S proteins (SARS-CoV-2 S-I53-50NPs), 166

the pooled trimer fractions were incubated overnight at 4°C with I53-50B.4PT1 in an 167 equimolar ratio. The nanoparticle preparation was further purified using an additional SEC 168 step to remove unassembled components. Negative-stain electron microscopy (nsEM) of the 169 pooled higher molecular weight fractions revealed a considerable portion of monodisperse 170

and well-ordered icosahedral nanoparticles ( Figure 1C ). Bio-layer-interferometry (BLI)-based 171

binding experiments with a panel of SARS-CoV-2 S protein-specific monoclonal NAbs, 172

previously isolated from recovered COVID-19 patients (Brouwer et al., 2020) , showed strong 173

binding of RBD-specific COVA1-18, COVA2-02, COVA2-15 and COVA2-39, and N-terminal 174 domain (NTD)-specific COVA1-22, to trimeric SARS-CoV-2 S-I53-50A.1NT1 and SARS-175

CoV-2 S-I53-50NP ( Figure 1D ). This suggests that presentation of SARS-CoV-2 S on I53-176 50NPs did not compromise the structure of these S protein epitopes. Altogether, SEC, nsEM 177

and BLI confirmed the successful generation of nanoparticles presenting multiple copies of 178 the SARS-CoV-2 S protein.

As approximately a third of the mass of the SARS-CoV-2 S protein consists of N-linked 181 glycans, we sought to identify the site-specific glycosylation of S protein presented on I53-182 50NPs using liquid chromatography-mass spectrometry (LC-MS). All sites presented high 183 levels of occupancy, with only N1074 displaying 15% of sites lacking an N-linked glycan 184

( Figure S1A ). The compositions of glycans present at the 19 N-linked glycan sites on the S 185 protein were determined and revealed a diverse range of structures ( Figure S1B ). Under-186 processed oligomannose-type glycans were observed at sites N61, N234, N717, N801 and 187 to a lesser extent at N1098. The average oligomannose-type glycan content across all sites 188 was 11%. Processed complex-type glycans were observed at all sites and were highly 189 fucosylated (73%), but mostly lacked sialylation (8%) (Figures S1A and S1B). The We assessed the immunogenicity of SARS-CoV-2 S-I53-50NPs in two small animal models.

Eight BALB/c mice were immunized with 10 µg of SARS-CoV-2 S presented on I53-50NPs, 219

adjuvanted in polyinosinic-polycytidylic acid (Poly-IC). In addition, five New Zealand White 220 rabbits were immunized with 30 µg of SARS-CoV-2 S presented on I53-50NPs, adjuvanted 221 in squalene emulsion. Mice and rabbits received three subcutaneous and intramuscular 222

immunizations, respectively, at week 0, 4 and 12 ( Figure 3A ). The adjuvants were chosen 223 based on our previous positive experiences with them in the respective animal models.

Two weeks after the first immunization, mice and rabbits induced detectable SARS-CoV-2 S 226 protein-specific immunoglobulin G (IgG) titers, as determined by an enzyme-linked 227 immunosorbent assay (ELISA), with a median endpoint binding titer of 2,920 and 5,105 228 respectively. In mice, median endpoint titers were further boosted after the second 229 immunization to 57,943 at week 6 and slightly decreased after the third, to 47,643 at week 230 14 ( Figure 3B ). In rabbits, median endpoint titers were boosted to 544,503 at week 6 and 231 594,292 at week 14 ( Figure 3C ). Neutralization of SARS-CoV-2 pseudovirus was already 232 detectable in the majority of mice and rabbit sera two weeks after the first immunization. NAb 233 titers, which are represented by the inhibitory dilutions at which 50% neutralization is 234 attained (ID 50 values), increased to a median of 16,792 at week 6 and 49,039 at week 14 in 235 mice ( Figure 3D and Table S1 ). In rabbits, NAb titers were boosted to a median ID 50 of 236 68,298 and 135,128 at week 6 and 14, respectively ( Figure 3E and Table S1 ). Neutralization 237 titers of authentic SARS-CoV-2 virus at week 14 reached a median ID 50 of 4,065 and 15,110 238 in mice and rabbits, respectively (Figures 3D and 3E, and Table S1 ). Collectively, we 239

showed that SARS-CoV-2 S-I53-50NPs were able to induce robust binding and NAb 240 responses in both mice and rabbits after two and three immunizations. The high binding and neutralization titers in mice and rabbits supported subsequent 246 assessment of the immunogenicity of SARS-CoV-2 S-I53-50NPs in cynomolgus macaques; 247 an animal model that is immunologically closer to humans. Six cynomolgus macaques were 248

immunized with 50 µg of SARS-CoV-2 S-I53-50NPs formulated in monophospholipid A 249 (MPLA) liposomes by the intramuscular route at week 0, 4 and 10 ( Figure 4A) To analyze the frequency of S protein and RBD-specific IgG-positive B cells in macaques 256 after vaccination, peripheral blood mononuclear cells at week 12 were gated on the 257 expression of CD20 and IgG and stained with fluorescently labeled prefusion SARS-CoV-2 S 258 protein or RBD ( Figure 4B ). We observed a clear expansion of SARS-CoV-2 S protein-259 specific B cells by vaccination, which constituted on average about 1% of total B cells 260

( Figure 4C ). Within the population of IgG-positive SARS-CoV-2 S protein-specific B cells, on 261 average around 30% bound to the RBD ( Figure 4C ). Within the CD27+ B cell population 262

(marker for memory B cells) an average 0.77% was SARS-CoV-2 S protein-specific, of 263 which, again, around 30% were specific for the RBD ( Figure S2 ). In addition to B cells, 264

SARS-CoV-2 S protein-specific T cells were also markedly expanded, as determined by an 265 enzyme-linked immune absorbent spot assay (ELISpot) ( Figure 4D) Within CD4-T cells (CD8+ T cells by inference), a trend towards higher expansion of cells 271

was observed in the vaccinated macaques ( Figure S3D ) 272 273

Sera of the immunized macaques exhibited SARS-CoV-2 S protein-specific binding IgG 274 responses with median endpoint titers of 211, 1,601 and 2,190, at week 2, 6, and 12, 275 respectively ( Figure 5A ). To compare binding titers to SARS-CoV-2 S protein and RBD 276 between sera from vaccinated macaques and those from convalescent humans from the 277 COSCA cohort (sampled approximately 4 weeks post onset of symptoms) (Brouwer et al. 278 2020), a different ELISA protocol was used. Specifically, binding responses were compared 279

to a standard curve of species-specific polyclonal IgG so that a semi-quantitative measure of 280 specific IgG concentrations could be obtained. Week 6 and 12 sera elicited markedly higher 281

IgG binding titers to SARS-CoV-2 S protein than serum from convalescent humans ( Figure  282 5B). This was also the case for RBD-specific binding titers ( Figure 5C ). 283

Using a custom Luminex bead-based serological assay, we analyzed the induction of 284 several Ig isotypes in serum, nasopharyngeal swab and saliva samples of the vaccinated 285 macaques over time. S protein-specific IgG levels in serum showed a similar course as 286 observed by ELISA ( Figure 5D and Figure S4A ). This was also the case for IgA, albeit with a 287 more rapid onset and waning after vaccination. As expected, IgM levels peaked after the first 288 immunization and gradually waned thereafter; presumably a result of Ig class-switching 289

( Figure 5D and Figure S4A ). We also observed an increase in S-specific IgG and IgA levels 290

in nasopharyngeal swabs and saliva after consecutive immunizations. This was particularly 291 clear for IgG in nasopharyngeal swabs ( Figure 5D and Figure S4B ). The results in saliva 292 samples were more variable ( Figure 5D and Figure S4C ). Thus, in addition to a systemic 293 antibody response, SARS-CoV-2 S-I53-50NPs induced detectable mucosal IgA and IgG 294 responses; a relevant finding considering that the respiratory mucosa is the first port of entry 295

for SARS-CoV-2 (Sungnak et al., 2020). Finally, we analyzed the ability of SARS-CoV-2 S 296 protein-specific serum Abs to bind to immune proteins that play a role in Fc-mediated 297 effector functions. The levels of FcγRIIa, FcγRIIIa and C1q binding tracked with IgG levels, 298

suggesting that the induced IgGs can perform effector functions such as antibody-dependent 299 cellular-cytotoxicity, phagocytosis and complement activation ( Figure S4D ). 300

Serum neutralization titers in the vaccinated macaques were overall robust. Already two 301

weeks after the first immunization, macaques induced pseudovirus neutralization with a 302 J o u r n a l P r e -p r o o f median ID 50 of 475. The second immunization increased the neutralization titers to a median 303 ID 50 of 8,865 which then declined only modestly up to the third immunization. NAb titers were 304 further increased to a median ID 50 of 26,361 at week 12 ( Figure 5E and Table S2 ). At week 6 305 the neutralization titers were similar to those in sera from convalescent humans but 306 neutralization titers at week 12 were significantly higher in vaccinated macaques than 307 convalescent humans (median ID 50 of 26,361 vs 8,226, p = 0.0012) ( Figure 5F ). 308

Neutralization of authentic SARS-CoV-2 was lower than that of pseudovirus but remained 309 potent (median ID 50 of 1,501 and 3,942 at week 6 and 12, respectively) ( Figure 5G and 310 Table S2 ). 311 312 SARS-CoV-2 S-I53-50NP vaccination protects cynomolgus macaques from high-dose 313 SARS-CoV-2 challenge 314 315

To assess the protective potential of SARS-CoV-2 S-I53-50NPs, vaccinated macaques and 316

contemporaneous control macaques (n=4) were infected with a total dose of 1 x 10 6 plaque-317

forming units (PFU) of a primary SARS-CoV-2 isolate (BetaCoV/France/IDF/0372/2020; 318 passaged twice in VeroE6 cells) by combined intra-nasal (0.25 mL in each nostril) and intra-319 tracheal (4.5 mL in the trachea) routes at week 12, two weeks after the final immunization. for viral RNA, as early as 1 day post exposure (dpe). In tracheal samples, viral loads peaked 325 between 1 and 3 dpe, with a median value of 6.9 log 10 copies/mL. Subsequently, viral loads 326

progressively decreased and all animals had undetectable viral loads by 14 dpe ( Figure 6A  327 and Figure S5 ). Similar profiles were observed in nasopharyngeal swabs, although viral 328 loads remained detectable in some macaques at 14 dpe ( Figure 6A and Figure S5 ). Viral 329 loads were markedly lower in rectal samples but stayed above the limit of detection during 330 the course of sampling for 2/4 control macaques ( Figure S5 ). Viral subgenomic (sg)RNA, 331

which is believed to reflect viral replication, peaked at 2 dpe in tracheal and nasopharyngeal 332 swabs (median viral sgRNA load 4.8 and 6.1 log 10 ,respectively) and were still detectable (> 333 2.5 log 10 copies/mL of viral sgRNA) at 5 and 6 dpe in the nasopharynx for 3 and 2 animals, 334 respectively ( Figure 6B ).

In vaccinated macaques, median peak viral loads were 300-fold lower in tracheal samples 337 (6.8 log 10 vs 4.3 log 10 ; p = 0.0095) and 500-fold lower in nasopharyngeal samples compared 338

to unvaccinated controls (7.9 log 10 vs 5.2 log 10 ; p = 0.0095). With the exception of MF7, all 339 vaccinated animals had undetectable loads at 6 dpe in tracheal and nasopharyngeal swabs 340

( Figure 6A and Figure S5 ). In addition to the upper airways, SARS-CoV-2 S-I53-50NP 341 vaccination significantly decreased viral loads in the lower airways, as demonstrated by a 342

275-fold lower median viral load in the bronchoalveolar lavage (BAL) ( 6.5 log 10 vs 4.1 log 10 ; 343 p = 0.0095). Viral replication was also significantly reduced in vaccinated animals. Only 2 out 344 of 6 vaccinated animals (MF5 and MF6) showed detectable sgRNA in the trachea at 2 dpe 345

and median viral loads were 160-fold lower than in control animals (4.7 log 10 vs 2.5 log 10 ; p = 346 0.0095). In the nasopharynx, sgRNA remained below the limit of detection at any of the 347 timepoints. At 2 dpe, median sgRNA loads in the vaccinated animals were 5400-fold lower 348 than in controls (6.2 log 10 vs 2.5 log 10 ; p = 0.0048) ( Figure 6B ). In BAL samples we observed 349 a 120-fold reduction of median sgRNA at day 3 dpe (4.6 log 10 vs 2.5 log 10 ; p = 0.0048) 350

( Figures 6A and 6B ).

An anamnestic response after challenge (i.e. an increase in (N)Ab titers following challenge 353

after vaccination) implies that vaccination is unable to induce sterilizing immunity. We 354 observed no increase in median NAb titers in vaccinated macaques at 2, 3 and 6 weeks 355 after challenge, in contrast to the control animals ( Figure S6 ). Instead, NAbs titers generally 356 J o u r n a l P r e -p r o o f continued to wane, suggesting that vaccine-induced immunity rapidly controlled infection 357

following challenge, preventing a boost of the immune system.

To assess the potential emergence of viral escape mutants in macaques after challenge, 360 viral variants in the challenge inoculum, nasal swabs at 3 and 5 dpe, and in BAL at 3 dpe 361

were sequenced. Two main viral variants were identified in the inoculum (V367F in the S 362 protein and G251V in ORF3a), which were later also found in the nasopharyngeal swabs 363

and BAL samples. A median of 6 subclonal mutations were found per sample over all 364

corresponding time points and anatomical sites, but no major differences were observed 365 between control and vaccinated animals ( Figure 6C ). The majority of the variants observed 366

in ORF1ab were mostly missense mutations, and consisted of a C>T nucleotide change 367

( Figure S6D and Table S3 ). A distinct variant in the S sequence arose in 2 vaccinated 368 macaques at day 3 in the nasopharyngeal swab but disappeared at day 5 post challenge, 369

suggesting that no NAb escape mutations emerged in vaccinated animals ( Figure 6C ). 14 dpe all contemporaneous and historical control animals showed mild pulmonary lesions 375 characterized by non-extended ground-glass opacities (GGOs) detected by chest computed 376 tomography (CT) ( Figure 6D ). By contrast, only 3 out of 6 vaccinated animals showed low 377

CT scores characteristics of mild and non-extended GGOs. Of note, the vaccinated 378 macaque (MF6) with the highest CT score at day 14 showed the lowest S protein and RBD 379 binding titers, the lowest NAb titers, and the highest viral load and sgRNA at day 5 pe. 380

Whereas all control animals experienced lymphopenia at 2 dpe, corresponding probably to 381 the installation of the response to infection, lymphocyte counts remained stable after 382 challenge for the vaccinated macaques ( Figure 6E and Figure S6 ), in agreement with the 383 absence of detectable anamnestic response. Together, these data further support that 384 vaccination with SARS-CoV-2 S-I53-50NPs reduces the severity of infection.

The development and distribution of a protective vaccine is paramount to bring the SARS-389

CoV-2 pandemic to a halt. Over the last months, numerous vaccine candidates of different illustrating the feasibility of large-scale GMP-production. Here, we show that I53-50NPs 399

presenting twenty copies of pre-fusion SARS-CoV-2 S protein induce robust NAb responses 400 in mice, rabbits and cynomolgus macaques. Vaccination of the latter prevented 401 lymphopenia, reduced lung damage and significantly reduced viral loads and replication in 402

both the upper and lower respiratory tract, suggesting that SARS-CoV-2 S-I53-50NPs could 403

reduce the risk of severe SARS-CoV-2-associated pathology in vaccinated humans and 404

control viral shedding and transmission.

Evidence is mounting that NAb titers are the immunological correlate of protection for SARS-407

CoV-2 (Addetia et al. 2020; Yu et al., 2020), and it is increasingly accepted that a successful 408 SARS-CoV-2 vaccine will need to induce potent NAb responses. We observed notable 409 differences in NAb titers by our vaccine and previously described candidates, although 410 here. On the other hand, our regimen consisted of three immunizations, a number that may 430 not be practical in the context of large scale vaccination campaigns. However, even though 431 three immunizations were used, the high NAb titers at week 6 indicate that two 432

immunizations may be sufficient to confer protection. As in the Novavax study, the animals 433

here were challenged 2 weeks after the final immunization (i.e. at peak NAb titer). It is 434 therefore difficult to draw conclusions on the durability of the protection, but we note that 435 SARS-CoV-2 memory B cells are expected to remain stable over a long period of time 436 (Gaebler et al., 2020) . Collectively, the rapid decrease in sgRNA levels, low level of viral 437 mutations in the S protein, and the absence of an anamnestic response after challenge, 438 emphasize SARS-CoV-2 S-I53-50NP vaccination's profound ability to control infection and 439

replication.

We propose two factors that may have been responsible for the potent humoral responses alternative administration route may allow SARS-CoV-2 S-I53-50NPs to elicit protective NAb 457 titers in the mucosa and could advance its protective efficacy towards fully sterilizing 458

immunity.

Limitations of study 461 462

The data presented here show that three immunizations with SARS-CoV-2 S-I53-50NPs can 463

induce protective immunity to a high-dose SARS-CoV-2 challenge. There are some 464 J o u r n a l P r e -p r o o f limitations in our study that we should note. First, we challenged the macaques two weeks 465

after the final immunization generally corresponding to the peak of NAb titers. We therefore 466 cannot ascertain that our vaccine would be as efficacious in the context of a delayed SARS-467

CoV-2 exposure. Second, our regimen included three immunizations, i.e. one more than 468 vaccines currently in use or under consideration. Emerged viral variants found by viral sequencing, in nasopharyngeal swabs at 3 dpe (left) 622

and 5 dpe (middle), and in BAL at 3 dpe. Colors indicate the ORFs in which mutations were 623

found, as depicted in the legend below. For a list of all identified variants see Table S3 . Note Mann-Whitney U test (*, p < 0.05; **, p < 0.01). 631

Resource availability 634 635

Lead Contact 636

Further information and requests for resources and reagents should be directed to and will 637 be fulfilled by the lead contact, Rogier W. Sanders Ni-NTA eluates of SARS-CoV-2 S-I53-50A.1NT1 (expressed as described above) were 745 buffer exchanged to Tris-buffer-saline (TBS), sterile filtered (0.22 µm) and applied to a 746

Superose 6 increase 10/300 GL column (GE healthcare) linked to a NGC chromatography 747 system (Bio-Rad) in TBS supplemented with 5% glycerol. Size exclusion fractions between 748

12-14 mL were pooled and an equimolar amount of I53-50B.4PT1 was added. After an 749 overnight incubation at 4°C, the assembly mix was applied to a Superose 6 increase 10/300 750 GL column in TBS+5% glycerol to remove unassembled components. Fractions 751

corresponding to assembled SARS-CoV-2 S-I53-50NPs (8.5-9.5 mL) were collected and 752 concentrated using Vivaspin columns with a molecular weight cutoff of 10,000 kDa (GE 753

Healthcare). Protein concentrations were determined by the Nanodrop method using the 754 proteins peptidic molecular weight and extinction coefficient as determined by the online 755

ExPASy software (ProtParam SARS-CoV-2 S-I53-50A.1NT1 and SARS-CoV-2 S-I53-50NP were diluted to 100 nM and 769 5nM, respectively, in BLI running buffer (PBS/0.1% bovine serum albumin/0.02% Tween20) 770

and antibody binding was assessed using a ForteBio Octet K2. The binding assays were 771

performed at 30°C and with agitation set at 1000 rpm. Antibody was loaded on protein A 772 sensors (ForteBio) at 10 µg/mL in running buffer until a binding threshold of 1 nm was 773

reached. Association and dissociation were measured for 300 s. 774

Gycopeptide analysis was essentially performed as described previously (Watanabe et al., 776 2020). A 30 µg aliquot of SARS-CoV-2 S-I53-50A.1NT1 was denatured, alkylated, reduced 777

and cleaved by the proteases trypsin, chymotrypsin and alpha-lytic protease. Clean-up of the 778 resulting peptide/glycopeptides was performed using C18 Zip-tips and the sample was 779 analysed by nanoLC-ESI MS with an Easy-nLC 1200 (Thermo Fisher Scientific) system 780 coupled to a Fusion mass spectrometer (Thermo Fisher Scientific) using higher energy 781 collision-induced dissociation (HCD) fragmentation. Peptides were separated using an 782

EasySpray PepMap RSLC C18 column (75 µm × 75 cm). Glycopeptide fragmentation data 783 were extracted from the raw file using Byonic TM (Version 3.5) and Byologic TM software 784 (Version 3.5; Protein Metrics Inc.).

Generation

The Following 30 s of baseline measurement, aliquots of 1 million cells/mL were then stimulated 810

for 100 s at RT with either 5 µg/mL, 1 µg/mL, 200 ng/mL or 40 ng/mL of SARS-CoV-2 S-I53-811

50A.1NT1 or the equimolar amount presented on I53-50NPs. Ionomycin (Invitrogen) was 812 added to a final concentration of 1 mg/mL to determine the maximum Indo-1-fluorescence.

Kinetics analyses were performed using FlowJo v10.7.

Animals and study designs 816

Cynomolgus macaques were randomly assigned in two experimental groups. The 817 vaccinated group (n=6) received 50 ug of SARS-CoV-2 S-I53-50NP adjuvanted with 500 µg 818 of MPLA liposomes (Polymun Scientific, Klosterneuburg, Austria) diluted in PBS at weeks 0, 819 4 and 10, while control animals (n=4) received no vaccination. Vaccinated animals were 820 sampled in blood, nasal swabs and saliva at weeks 0, 2, 4, 6, 8, 10 and 12. At week 12, all 821 animals were exposed to a total dose of 10 6 pfu of SARS-CoV-2 virus (hCoV-19/France/ 822 lDF0372/2020 strain; GISAID EpiCoV platform under accession number EPI_ISL_406596) 823

via the combination of intranasal and intra-tracheal routes (0,25 mL in each nostril and 4,5 824 mL in the trachea, i.e. a total of 5 mL; day 0), using atropine (0.04 mg/kg) for pre-medication 825

and ketamine (5 mg/kg) with medetomidine (0.042 mg/kg) for anesthesia. Saliva, as well as 826 nasopharyngeal, tracheal and rectal swabs, were collected at days 1, 2, 3, 4, 5, 6, 10, 14 827

and 21 days past exposure (dpe) while blood was taken at days 2, 4, 6, 10, 14 and 21 dpe. 828

Bronchoalveolar lavages (BAL) were performed using 50 mL sterile saline on 3 dpe. A single 829

BAL was performed at 3 dpe in order to be close to the peak of viral replication and to be 830 able to observe a difference between the vaccinated and control groups. In our earlier study 831 (Maisonnasse et al., 2020), we found that at later time-points, viral loads in the BAL were 832 very low or negative. Chest CT was performed at baseline and on 3, 7 and 14 dpe in 833

anesthetized animals using tiletamine (4 mg/kg) and zolazepam (4 mg/kg). Blood cell 834 counts, haemoglobin and haematocrit were determined from EDTA blood using a HMX A/L 835 analyzer (Beckman Coulter). 836 837 J o u r n a l P r e -p r o o f Female New Zealand White rabbits were given two intramuscular immunizations, one in 838 each quadricep, at weeks 0, 4, and 12. The immunization mixture involved 39 µg of SARS-839

CoV-2-S-I53-50NPs (equal to 30 µg of SARS-CoV-2-S) formulated 1:1 in Squalene 840

Emulsion adjuvant (Polymun, Klosterneuburg, Austria). The rabbits were bled on the day of 841

immunization and then at weeks 2, 4, 6, and 14.

Female Balb/cAnNCrl mice received subcutaneous immunizations into the neck skin-fold at 844 weeks 0, 4, and 12. The immunization mixture contained 13 µg of SARS-CoV-2-S-I53-845

50NPs (equal to 10 µg of SARS-CoV-2-S) adjuvanted with 50 µg of polyinosinic-polycytidylic 846 acid (Poly-IC; Invivogen). Blood was collected at weeks -1, 2, 6 and 14. Two out of eight 847 mice were sacrificed at week 6 to allow interim analysis of the induced humoral response.

Patient samples 850

Patients with at least one nasopharyngeal swab positive for SARS-CoV-2 as determined by 851

qRT-PCR (Roche LightCycler480, targeting the Envelope-gene 113bp) were included. 852

Patients using immunosuppressive mediation (equivalent of >7.5 mg prednisolone) were 853 excluded from the study. Biotinylated SARS-CoV-2 S protein and RBD were conjugated to streptavidin-bound 999

fluorophores. Briefly, the biotinylated proteins were incubated for a minimum of 1 h at 4°C 1000 with the streptavidin-conjugates AF647 (Biolegend), BV421 (Biolegend) and BB515 (BD 1001

Biosciences) at a 1:2 protein to fluorochrome ratio. The fluorescent probes were incubated 1002 experiments were performed using 5 animals. In the macaque experiments, 6 animals were 1112 used in the vaccinated group and 4 animals were used in the control group. 1113 1114 Supplemental Information titles and legends 1115 1116 Figure S1 . Site-specific glycan analysis of SARS-CoV-2 S I53-50NPs, related to Figure  1117 1. Table S3 . 1189 1190 Table S3 . Viral variants identified by viral sequencing in control and vaccinated 1191 cynomolgus macaques after challenge, related to figure 6. 1192 1193

Neutralizing antibodies correlate with protection 1197 from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate

Introduction of two prolines and removal of the polybasic 1201 cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in 1202 the mouse model

Structural and functional 1205 evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer 1206 immunogens

Vaccine delivery: a matter of size, geometry, 1208 kinetics and molecular patterns

Accurate design of megadalton-scale two-component 1211 icosahedral protein complexes

Elicitation of broadly protective 1214 immunity to influenza by multivalent hemagglutinin nanoparticle vaccines

Silencing of HIV-1 1217 with RNA Interference: a Multiple shRNA Approach

Enhancing and shaping the 1220 immunogenicity of native-like HIV-1 envelope trimers with a two-component protein 1221 nanoparticle

Potent neutralizing 1224 antibodies from COVID-19 patients define multiple targets of vulnerability

Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-1231

Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Evaluation of the mRNA-1273

Vaccine against SARS-CoV-2 in Nonhuman Primates

Detection of 2019 novel coronavirus 1237 (2019-nCoV) by real-time RT-PCR

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

A 1243 third-generation lentivirus vector with a conditional packaging system

Longshot enables accurate variant calling in diploid 1245 genomes from single-molecule long read sequencing

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-1248 COV-2 challenge in rhesus macaques

Evolution of Antibody 1251 Immunity to SARS-CoV-2. bioRxiv

Development of an inactivated vaccine candidate for SARS-CoV-2

Extracellular nanovesicles for packaging of 1257 CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping

UCSF ChimeraX: Meeting modern challenges in visualization and 1261 analysis

NVX-CoV2373 vaccine protects 1264 cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

A Single-Dose Intranasal ChAd

Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

Self-assembling nanoparticles presenting receptor binding domain and stabilized 1272 spike as next-generation COVID-19 vaccines

Vaccination establishes clonal 1276 relatives of germinal center T cells in the blood of humans

Structure-based design of prefusion-1279 stabilized SARS-CoV-2 spikes

Stabilizing the Closed SARS-CoV

Self-assembling influenza 1285 nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

Immunological basis for enhanced 1287 immunity of nanoparticle vaccines

Immunogenicity of clinically relevant 1289 SARS-CoV-2 vaccines in non-human primates and humans

VarScan 2: somatic mutation and copy 1292 number alteration discovery in cancer by exome sequencing

Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat 1295 separation

A highly 1298 stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

Immunogenicity, reactogenicity and safety of 2 doses of an 1302 adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older 1303 adults: Results of a phase III, randomized, open-label, multicenter study

Appion: an integrated, database-driven 1307 pipeline to facilitate EM image processing

Clinical and 1310 virological data of the first cases of COVID-19 in Europe: a case series

Minimap2: pairwise alignment for nucleotide sequences

S-Trimer, a COVID-1315 19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Self-assembling 1318 protein nanoparticles in the design of vaccines

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and

HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Hydroxychloroquine use against 1325 SARS-CoV-2 infection in non-human primates

Induction of Potent Neutralizing 1328

Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial 1329 Virus

HIV antibodies. Antigen modification regulates competition of 1332 broad and narrow neutralizing HIV antibodies

Single-shot Ad26 vaccine protects against 1335 SARS-CoV-2 in rhesus macaques

Beyond antigens and adjuvants: 1337 formulating future vaccines

Severe Acute

Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 1341 Patients

Immunogenicity and structures of a 1344 rationally designed prefusion MERS-CoV spike antigen

Time Course of Lung Changes at Chest CT during Recovery from 1348

COVID-19)

Intradermal-delivered DNA vaccine 1351 provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. 1352 bioRxiv

Leginon: a system for fully automated 1355 acquisition of 1000 electron micrographs a day

A single immunization with spike-functionalized ferritin 1358 vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice

Isolation of potent SARS-CoV-2 neutralizing antibodies 1362 and protection from disease in a small animal model

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

Stabilization of the 1369 soluble, cleaved, trimeric form of the envelope glycoprotein complex of human 1370 immunodeficiency virus type 1

CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Cell entry 1376 mechanisms of SARS-CoV-2

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a 1379 descriptive study

Presenting native-like

HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity

Structure and immunogenicity of a 1386 stabilized HIV-1 envelope trimer based on a group-M consensus sequence

SARS-CoV-2 entry factors are 1390 highly expressed in nasal epithelial cells together with innate immune genes

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-1395 neutralizing Epitopes

SARS-CoV-2 spike glycoprotein vaccine 1398 candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

Innate immune recognition of glycans 1402 targets HIV nanoparticle immunogens to germinal centers

Improvements to the ARTIC multiplex 1405 PCR method for SARS-CoV-2 genome sequencing using nanopore

T follicular helper cells in human 1409 efferent lymph retain lymphoid characteristics

Role of nanoscale antigen 1413 organization on B-cell activation probed using DNA origami

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Elicitation of potent neutralizing antibody 1419 responses by designed protein nanoparticle vaccines for SARS-CoV-2

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, 1422 with Potent Protection against SARS-CoV-2

Site-specific 1424 glycan analysis of the SARS-CoV-2 spike

Virological assessment of hospitalized 1427 patients with COVID-2019

Cryo-EM structure of the 2019-nCoV spike in the prefusion 1430 conformation

Molecular Architecture of the SARS-CoV-2 Virus

DNA vaccine protection against SARS-1435

CoV-2 in rhesus macaques

Highlights • Two-component protein nanoparticles display multiple copies of the SARS-CoV-2 Spike • Spike protein nanoparticles enhance cognate B cell activation in vitro • Vaccination induces potent neutralization in mice, rabbits and cynomolgus macaques • Vaccination protects macaques against a high-dose SARS-CoV-2 challenge

for at least 10 min with 10mM biotin (GeneCopoeia) to saturate the unconjugated 1003 streptavidin-fluorochrome complexes. Cryopreserved macaque PBMCs from 2 weeks after 1004 final immunization (week 12) were thawed and counted. 5x10 6 cells were stained for 30 min 1005at 4°C with the fluorescent probes, a viability marker (LiveDead-eF780, eBiosciences) and 1006 the following B cell-specific antibodies: anti-CD20-PE-CF594 (clone 2H7; BD Biosciences), 1007anti-IgG-PE-Cy7 (clone G18-145;BD Biosciences), anti-CD27-PE (clone M-T271; BD 1008Biosciences), and anti-IgM-BV605 (clone MHM-88; Biolegend). Cells were washed twice 1009with FACS buffer and acquired on the FACS-ARIA-SORP 4 laser (BD Biosciences Upper respiratory (nasopharyngeal and tracheal) and rectal specimens were collected with 1031swabs (Viral Transport Medium, CDC, DSR-052-01). Tracheal swabs were performed by 1032insertion of the swab above the tip of the epiglottis into the upper trachea at approximately 1033 1.5 cm of the epiglottis. All specimens were stored between 2°C and 8°C until analysis by 1034RT-qPCR with a plasmid standard concentration range containing an RdRp gene fragment 1035including the RdRp-IP4 RT-PCR target sequence. SARS-CoV-2 E gene subgenomic mRNA 1036(sgmRNA) levels were assessed by RT-qPCR using primers and probes previously 1037 described ( detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2).

Chest computed tomography and image analysis 1046Acquisition was done using a computed tomography (CT) system (Vereos-Ingenuity, 1047Philips). Animals were anesthetized and put in a supine position. Body temperature, oxygen 1048 saturation and heart rate were monitored. The collimation of the CT detector was 64 x 0.6 1049 mm, with a 120 kV tube voltage and around 120 mA intensity. The intensity was regulated by final results were made by consensus. Overall CT scores include the lesion type, scored 1057 from 0 to 3 (None, 0; Slight, 1; Mild, 2; Severe, 3) and lesion volume, scored from 0 to 4 1058 (None, 0; < 25% of the lobe, 1; 25 < x < 50% of the lobe, 2; 50 < x < 75% of the lobe, 3; 75 < 1059x < 100% of the lobe; 4) and summed for each lobe. schemes/tree/master/nCoV-2019/V3) was used to perform the multiplex PCR for SARS-1079CoV-2. All samples were run for 35 cycles in the two multiplex PCRs. Pooled and cleaned 1080 PCR reactions were quantified using QubitTM fluorometer (Invitrogen). The Ligation 1081Sequencing kit (SQK-LSK109; Oxford Nanopore Technologies) was used to prepare the 1082 library following the manufacturer's protocol ("PCR tiling of COVID-19 virus", release F; 1083Oxford Nanopore Technologies). 24 samples were multiplexed using Native Barcoding 1084Expansion 1-12 and Native Barcoding Expansion 13-24 kits (EXP-NBD104 and EXP-1085 NBD114; Oxford Nanopore Technologies). Two libraries of 24 samples were prepared 1086independently and quantified by QubitTM fluorometer (Invitrogen). Quality control of two 1087R9.4 flowcells (FLO-MIN106; Oxford Nanopore Technologies) was performed to assess 1088 pores viability. Next, 45 and 32 ng of library were respectively loaded as recommended by 1089 the manufacturer's protocol. Sequencing was performed on a GridION (Oxford Nanopore 1090Technologies) for 72 h with high-accuracy Guppy basecalling (v3.2.10). After sequencing, 1091demultiplexing was performed using Guppy v4.0.14 with the option --1092 require_barcodes_both_ends to ensure high quality demultiplexing. Reads were then filtered 1093 by Nanoplot v1.28.1 based on length and quality to select high quality reads. Then, reads 1094were aligned on the SARS-CoV-2 reference genome NC_045512.2 using minimap2 v2.17. 1095Primary alignments were filtered based on reads length alignment and reads identity. Finally, 1096variant calling was performed with Longshot v0.4.1. Identified variants were then analyzed 1097 using in-house scripts. Variants absent from the inoculum but present in one or more 1098 samples were selected for further analysis.

Quantification and statistical analysis 1101 1102Details on the statistical analysis for the experiments can be found in the accompanying 1103 figure legends. Statistical significance between groups is indicated in the figures by stars: *, 1104 p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. In addition, statistical significance 1105 between viral loads in the control and vaccinated groups are also indicated in the Results 1106 section by p values. Medians are plotted for all experiments and comparisons between two 1107 groups were made using a Mann-Whitney U test (Excel 2016, GraphPad Prism 8.0/7.0). For 1108 mouse experiments 8 animals were used up to week 6, when 2 animals were euthanized for 1109 preliminary assessment of (N)Ab titers. Due to low sample volumes the eight mouse 1110 samples at week -1 were randomly paired and pooled into 4 samples. The rabbit 1111